Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry

JOURNAL OF HEPATOLOGY

卷:75

Article

Stephens, Camilla^1,2,15  Robles-Diaz, Mercedes^1,2,15  Medina-Caliz, Inmaculada^1,2  Garcia-Cortes, Miren^1,2,15  Ortega-Alonso, Aida^1,2,15  Sanabria-Cabrera, Judith^1,2,16  Gonzalez-Jimenez, Andres^1,2  Alvarez-Alvarez, Ismael^1,2  Slim, Mahmoud^1,2  Jimenez-Perez, Miguel³  Gonzalez-Grande, Rocio³  Carmen Fernandez, M.⁴  Casado, Marta⁴  Soriano, German^5,15  Roman, Eva^5,6,15  Hallal, Hacibe⁷  Romero-Gomez, Manuel^8,15  Castiella, Agustin⁹  Conde, Isabel^10,15  Prieto, Martin^10,15  Maria Moreno-Planas, Jose¹¹  Giraldez, Alvaro¹²  Miguel Moreno-Sanfiel, J.¹³  Kaplowitz, Neil¹⁴  Isabel Lucena, M.^1,2,15,16  Andrade, Raul J.^1,2,15 

[1] Univ Malaga, Hosp Univ Virgen de la Victoria, Inst Invest Biomed Malaga IBIMA, UGC Aparato Digest, Malaga, Spain

[2] Univ Malaga, Hosp Univ Virgen de la Victoria, Inst Invest Biomed Malaga IBIMA, Serv Farmacol Clin, Malaga, Spain

[3] Complejo Hosp Reg Malaga, IBIMA, UGC Aparato Digest, Malaga, Spain

[4] Hosp Univ Torrecardenas, UGC Farm, Almeria, Spain

[5] Univ Autonoma Barcelona, Serv Gastroenterol, Hosp Santa Creu & St Pau, Barcelona, Spain

[6] Univ Autonoma Barcelona, Escola Univ Infermeria EUI St Pau, Barcelona, Spain

[7] Hosp Gen Univ JM Morales Meseguer, Serv Aparato Digest, Murcia, Spain

[8] Univ Seville, Hosp Univ Virgen del Rocio, SeLiver Grp IBIS, UGC Aparato Digest, Seville, Spain

[9] Hosp Univ Donostia, Serv Aparato Digest, San Sebastian, Spain

[10] Hosp Univ & Politecn La Fe, Serv Aparato Digest, Unidad Hepatol, Valencia, Spain

[11] Complejo Hosp Univ Albacete, Serv Digest, Albacete, Spain

[12] Hosp Virgen del Rocio, Serv Aparato Digest, Seville, Spain

[13] Hosp Univ Canarias, Serv Aparato Digest, Tenerife, Spain

[14] Univ Southern Calif, Keck Sch Med, Res Ctr Liver Dis, Los Angeles, CA 90007 USA

[15] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

[16] Platform ISCiii Clin Res & Clin Trials UICEC IBIM, Malaga, Spain

关键词: Hepatotoxicity;    DILI;    epidemiology;    liver-related death;    causative agents;    outcome;    risk factors;    therapy in DILI;    drug-induced autoimmune hepatitis;   

DOI  :  10.1016/j.jhep.2021.01.029

来源: Elsevier

【 摘 要 】

Background & Aims: Prospective drug-induced liver injury (DILI) registries are important sources of information on idiosyncratic DILI. We aimed to present a comprehensive analysis of 843 patients with DILI enrolled into the Spanish DILI Registry over a 20-year time period. Methods: Cases were identified, diagnosed and followed prospectively. Clinical features, drug information and outcome data were collected. Results: A total of 843 patients, with a mean age of 54 years (48% females), were enrolled up to 2018. Hepatocellular injury was associated with younger age (adjusted odds ratio [aOR] per year 0.983; 95% CI 0.974-0.991) and lower platelet count (aOR per unit 0.996; 95% CI 0.994-0.998). Anti-infectives were the most common causative drug class (40%). Liver-related mortality was more frequent in patients with hepatocellular damage aged >- 65 years (p = 0.0083) and in patients with underlying liver disease (p = 0.0221). Independent predictors of liver-related death/transplantation included nR-based hepatocellular injury, female sex, higher onset aspartate aminotransferase (AST) and bilirubin values. nR-based hepatocellular injury was not associated with 6-month overall mortality, for which comorbidity burden played a more important role. The prognostic capacity of Hy's law varied between causative agents. Empirical therapy (corticosteroids, ursodeoxycholic acid and MARS) was prescribed to 20% of patients. Drug-induced autoimmune hepatitis patients (26 cases) were mainly females (62%) with hepatocellular damage (92%), who more frequently received immunosuppressive therapy (58%). Conclusions: AST elevation at onset is a strong predictor of poor outcome and should be routinely assessed in DILI evaluation. Mortality is higher in older patients with hepatocellular damage and patients with underlying hepatic conditions. The Spanish DILI Registry is a valuable tool in the identification of causative drugs, clinical signatures and prognostic risk factors in DILI and can aid physicians in DILI characterisation and management. Lay summary: Clinical information on drug-induced liver injury (DILI) collected from enrolled patients in the Spanish DILI Registry can guide physicians in the decision-making process. We have found that older patients with hepatocellular type liver injury and patients with additional liver conditions are at a higher risk of mortality. The type of liver injury, patient sex and analytical values of aspartate aminotransferase and total bilirubin can also help predict clinical outcomes. (C) 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

【 授权许可】

Free